A novel SIRT5 inhibitor named NRD167 was shown to effectively inhibit SIRT5’s demalonylase activity in leukemia cells, causing an increase in protein malonylation and a corresponding block in leukemic growth (Li And Melnick 2021). Here, SIRT5 is linked to leukemia.